Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » JP Morgan Downgrades Illumina to Neutral on Grail Deal

JP Morgan Downgrades Illumina to Neutral on Grail Deal

Sep 21, 2020
|
staff reporter

NEW YORK – JP Morgan said on Monday afternoon that it is downgrading Illumina from an 'overweight' to a 'neutral' rating following Illumina's announcement earlier in the day that it plans to acquire cancer diagnostics company Grail for $8 billion in stock and cash. The investment bank also lowered its December 2021 price target for Illumina from $390 to $280.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

P.1 Re-infection Concerns

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

Aiming for May

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

NIH Program to Address Structural Racism

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

PNAS Papers on Myelopathy GWAS in Japan, Hypertrophic Cardiomyopathy, MRSA Methylation

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.

Mar
09
Featured Webinar

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

Sponsored by
Fabric Genomics

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams. 

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

What's Popular?

In Sequencing

  1. Twist Bioscience, Watchmaker Genomics Partner on High-Throughput NGS Applications

  2. TGen-Led Team Spots Pediatric, Pancreatic Cancer From cfDNA Fragments in Urine

    Premium

  3. Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service

  4. New Method Provides NGS-Based Readout of Glycan Levels in Single Cells

    Premium

  5. Strata Oncology, Pfizer Partner to Explore New Biomarker Indications for FDA-Approved Drugs

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.